ProCE Banner Activity

An Expert’s Guide to the 2021 ASCO Genitourinary Cancers Symposium: A Preview of the Top Abstracts

Conference Coverage
Clinical Thought
Review experts’ perspectives on the most clinically relevant emerging data for genitourinary cancers to be presented at the 2021 Genitourinary Cancers Symposium annual meeting.

Released: February 04, 2021

Expiration: February 03, 2022

Share

Faculty

Robert Motzer

Robert Motzer, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Astellas Text

Eisai

Merck Sharp & Dohme Corp.

Seagen

Faculty Disclosure

Primary Author

Robert Motzer, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Robert J. Motzer, MD, has disclosed that he has received consulting fees from Eisai, Exelixis, Genentech/Roche, Merck, and Pfizer and funds for research support from Bristol-Myers Squibb, Eisai, Exelixis, Genentech/Roche, Lilly Oncology, and Pfizer.

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Exelixis, Incyte, Janssen, Lilly, Pfizer, Pharmacyclics, Roche, Seattle Genetics, and Urogen; has received funds for research support from Ada Cap (Advanced Accelerator Applications), Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Incyte, Genentech, Innocrin, Lilly, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche, Sanofi Aventis, Seattle Genetics; and has ownership interests in Bellicum and Tyme.